CASE REPORT

The effect of hormones on an uncommon breast disorder pseudoangiomatous stromal hyperplasia: a case report and literature review

Genevieve Hattingh¹,*, Mariam Ibrahim¹, Thomas Robinson² and Ajay Shah¹

¹Department of Surgery, Bronxcare Health System, Bronx, NY, USA and ²American University of the Caribbean School of Medicine, St. Maarten, Netherlands Antilles

*Correspondence address. Department of Surgery, 1650 Grand Concourse, Bronx, NY 10457.
Tel: (360) 820-1959; Fax: (718) 960-370; E-mail: ghatting@bronxcare.org.

Abstract

Pseudoangiomatous stromal hyperplasia (PASH) is a benign proliferation of the breast, with few cases reported to date. While the etiology of the disease is uncertain, a prevailing theory is that PASH is hormonally responsive, especially in the presence of progesterone. Literature review shows a correlation between PASH development and oral contraceptive pill (OCP) use. We report a case of a 28-year-old autistic female who underwent excision of palpable bilateral breast masses where the histology of the left breast mass identified as PASH. Our patient had a history of multiple medications including OCPs and cytochrome p450 inhibitors that could lead to an increase in progesterone levels. Thus, supporting a theory that medications, in addition to OCPs, may lead to an increased occurrence of PASH in pre-menopausal women.

INTRODUCTION

Pseudoangiomatous stromal hyperplasia (PASH) is an uncommon benign breast condition first described in 1986 [1]. With few reported cases to date, the lesion usually manifests as a palpable lump with similar characteristics to fibroadenomas; however, PASH is also frequently found incidentally on biopsies performed for other reasons [2]. According to the current state of literature, PASH tends to occur most frequently in pre-menopausal women [3], with an additional incidence of 24–47% in men who have gynecomastia [4]. Review of the literature has shown that elevated progesterone levels play a role on PASH. A current working hypothesis links the elevated progesterone levels due to oral contraceptive pills (OCPs), hormone stimulation or other medications to increased incidences of PASH [5].

Diagnosis of PASH is made on core needle biopsy or surgical excision incidentally. On ultrasound (US), PASH typically presents as an oval or round hypoechoic mass or as a heterogeneous mass with cystic areas [4]. On mammography, PASH is commonly described as a well-defined, non-calcified mass with regular borders and margins [4]. Histologically, it is characterized by inter-anastomosing, angulated and slit-like spaces lined by slender spindle cells and surrounded by dense collagenous stroma [3].

PASH may be mistaken for angiosarcoma but can be differentiated based on malignant cytological features and positive immunohistochemical staining of endothelial markers [3]. PASH itself is a benign entity and is not associated with an increased incidence of malignancy. However, PASH can coexist with malignant lesions; suspicious imaging findings should prompt further investigation.

Revised: November 8, 2020. Accepted: November 27, 2020
Published by Oxford University Press and JSCR Publishing Ltd. All rights reserved. © The Author(s) 2020.
A 28-year-old female was being followed by the breast surgical team since the age of 22 for abnormal breast lesions. She had a complex medical history significant for autism, developmental delay, seizure disorders and encephalitis at age 1. She has been on OCPs for contraception for the past 10 years. Her medications included Risperdal, Topamax, Klonopin and Trileptal. Family history was negative for any breast lesions or ovarian cancers.

She was first seen by the surgical team for left breast fibroadenoma that was removed at age 22. The team continued to follow the patient, and at age 24, a bilateral excisional breast biopsy was conducted. Pathology showed benign mammary tissue with lobular hyperplasia and adenosis. No further intervention was required and the patient was followed with US imaging at regular intervals.

At age 25, she presented with a palpable left and right breast lump. US found a Breast Imaging Reporting and Database System score (BIRADS) 3 lesion showing a right breast hypoechoic lesion at the 4 o'clock position that was approximately 1 cm in size with ill-defined margins. Following discussion with the patient and her family, the decision was made to manage conservatively with regular follow-up imaging and visits to the clinic. Her family assisted to ensure compliance. Six months later, her breast US revealed multiple lesions in both breasts, with an increase in size in the left breast lesion that was now reported as BIRADS 4. Her OCPs were stopped and conservative management continued. Three months later, her repeat US showed a decrease in the size of left breast lesion, which was reported as BIRADS 3.

With continued follow-up, it was noted a year later that she now had palpable breast masses. US again showed the left breast mass had grown from 5.8 cm a year ago to 8.6 cm and an additional right breast lesion. US was read as BIRADS 4. While benign diagnoses of fibroadenomas or fibrocystic changes were the most likely differentials, the decision was made to schedule the patient for surgery due to the size of the masses. The surgical team excised two right and two left breast lesions. The right breast tissue was consistent with fibroadenoma. The left breast tissue showed strands of collagen traversing some spaces and well-formed anastomosing spaces, slits outlined by myofibroblasts with uniform, small flat nuclei consistent with PASH. The patient had no complications from the surgery and was scheduled for a breast US 4 months post-operatively, having missed that appointment. US 1 year post-operatively was read as BIRADS 2. The patient's mother wanted to ensure yearly follow-ups with the current breast surgeon due to her extensive history of breast lesions.

DISCUSSION

PASH is an infrequent but not a rare major pathologic finding, present in ~6% of benign surgical breast biopsies [7]. It presents in both pre-menopausal and perimenopausal women. To date, the cause remains uncertain; however, a leading hypothesis is that hormonal stimulation plays a role [8], specifically progesterone stimulation. The literature shows a large quantity of progesterone receptor expression in PASH stromal cells, with estrogen receptors expression being more variable [5]. The hypothesis is supported by the fact that, like our patient, there is a higher incidence of PASH in pre-menopausal women [5]. The occurrence of PASH in males further supports the hormonal theory. Pre-menopausal women additionally have a higher usage of OCPs in this population and are at the peak of hormone expression [5].

The patient described in this case lends to credence to the hormonal hypothesis. Not only was she a pre-menopausal woman on OCPs, but her particular drug regimen could have led to elevated progesterone levels. Specifically, our patient was taking Klonopin, Risperdal, Topamax and Trileptal, all medications that interact with cytochrome P (CYP) 450 enzymes. Multiple hepatic CYPs enzymes are involved in the synthesis and metabolism of estrogen and progesterone. There are at least 17 hepatic CYPs that potentially can participate in the metabolism of steroids. Hepatic CYP enzymes accept a wide range of substrates and multiple CYPs can contribute to the same reaction [9]. Klonopin specifically inhibits CYPs that are directly involved in progesterone metabolism [5].
CONCLUSION
The inhibition of CYPs by Klonopin, resulting in increasing progestosterone levels, supports the hypothesis that drugs beyond OCPs may be involved in the development of PASH. We propose future research to investigate the association between PASH and CYP modulators to determine the pathogenesis and risk factors of this uncommon disease.

ACKNOWLEDGEMENTS
We would like to thank Dr Masooma Niazi, MD, Chairman of Pathology at the Bronx Care Health System for the pathology slides.

FUNDING
None.

CONFLICT OF INTEREST STATEMENT
None declared.

REFERENCES
1. Kareem Z, Iver S, Sing M. Pseudoangiomatous stromal hyperplasia: a rare cause of breast lump in a premenopausal female. J Clin Diagn Res 2017;11:PD02–3.
2. Radhi J, Alport E. Pseudoangiomatous stromal hyperplasia. Int J Angiol 2011;11:57–8.
3. Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, et al. Pseudoangiomatous stromal hyperplasia of the breast: multimodality review with pathologic correlation. Curr Probl Diagn Radiol 2017;46:130–5.
4. Bowman E, Oprea G, Okoli J, Gundry K, Rizzo M, Gabram-Mendola S, et al. Pseudoangiomatous stromal hyperplasia (PASH) of the breast: a series of 24 patients. Breast J 2012;18:242–7.
5. Surace A, Liberale V, D’Alonzo M, Pecchio S, Baù MG, Biglia N. Pseudoangiomatous stromal hyperplasia (PASH) of the breast: an uncommon finding in an uncommon patient. Am J Case Rep 2020;21:e919856.
6. Krawczyk N, Fehm T, Mohrmann S, Hoffmann J. Bilateral diffuse pseudoangiomatous stromal hyperplasia (PASH) causing gigantomastia in a 33-year-old pregnant woman: case report. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2015;12:356–8.
7. Degnim AC, Frost MH, Radisky DC, Anderson SS, Vierkant RA, Boughey JC, et al. Pseudoangiomatous stromal hyperplasia and breast cancer risk. Ann Surg Oncol 2010;17:3269–77.
8. Ferreira M, Albarracin CT, Resetkova E. Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases. Mod Pathol 2007;21:201–7.
9. Schiffer L, Barnard L, Baranowski ES, Gilligan LC, Taylor AE, Arlt W, et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review. J Steroid Biochem Mol Biol 2019;194:105439. doi: 10.1016/j.jsbmb.2019.105439.